Premium
Angiotensin II Type 2‐Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain
Author(s) -
Rice ASC,
Smith MT
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.29
Subject(s) - neuropathic pain , postherpetic neuralgia , medicine , peripheral , neuralgia , receptor antagonist , clinical trial , antagonist , receptor , pharmacology , anesthesia
Neuropathic pain is a large unmet medical need. The angiotensin II type 2 (AT 2 ) receptor is a target with promising data in rodent models of peripheral neuropathic pain.[1][Smith, M.T., 2013], [2][Smith, M.T., 2013], [3][Muralidharan, A., 2014], [4][Smith, M.T., 2014] The AT 2 receptor has attracted attention on the basis of human data from a proof‐of‐concept clinical trial showing that oral EMA401, a highly selective, peripherally restricted, small molecule AT 2 receptor antagonist, at 100 mg twice‐daily for 4 weeks, alleviated postherpetic neuralgia,[5][Rice, A.S., 2014] an often intractable type of peripheral neuropathic pain.